These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30637361)

  • 61. Risk factors of community-onset extended-spectrum β-lactamase Escherichia coli and Klebsiella pneumoniae bacteraemia: an 11-year population-based case-control-control study in Denmark.
    Richelsen R; Smit J; Laxsen Anru P; Schønheyder HC; Nielsen H
    Clin Microbiol Infect; 2021 Jun; 27(6):871-877. PubMed ID: 32781243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae from urinary tract infections: Evolution of antimicrobial resistance and treatment options.
    Jiménez-Guerra G; Heras-Cañas V; Béjar Molina LDC; Sorlózano-Puerto A; Navarro-Marí JM; Gutiérrez-Fernández J
    Med Clin (Barc); 2018 Apr; 150(7):262-265. PubMed ID: 28992981
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.
    Thaden JT; Fowler VG; Sexton DJ; Anderson DJ
    Infect Control Hosp Epidemiol; 2016 Jan; 37(1):49-54. PubMed ID: 26458226
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study.
    Almomani BA; Hayajneh WA; Ayoub AM; Ababneh MA; Al Momani MA
    Infection; 2018 Aug; 46(4):495-501. PubMed ID: 29748840
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multidrug resistance and risk factors associated with community-acquired urinary tract infections caused by Escherichia coli in Venezuela.
    Guzmán M; Salazar E; Cordero V; Castro A; Villanueva A; Rodulfo H; De Donato M
    Biomedica; 2019 May; 39(s1):96-107. PubMed ID: 31529852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study.
    Søgaard M; Heide-Jørgensen U; Vandenbroucke JP; Schønheyder HC; Vandenbroucke-Grauls CMJE
    Clin Microbiol Infect; 2017 Dec; 23(12):952-960. PubMed ID: 28377310
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urine of nonhospitalized patients in the Zagreb region].
    Marijan T; Plecko V; Vranes J; Dzepina AM; Bedenić B; Kalenić S
    Med Glas (Zenica); 2010 Feb; 7(1):46-53. PubMed ID: 20387724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli.
    Jo KJ; Yoo S; Song JY; Kim SH; Park SE
    Pediatr Neonatol; 2021 May; 62(3):271-277. PubMed ID: 33602619
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
    Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
    Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
    Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.
    Hu B; Ye H; Xu Y; Ni Y; Hu Y; Yu Y; Huang Z; Ma L
    Curr Med Res Opin; 2010 Jun; 26(6):1443-9. PubMed ID: 20394469
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.
    Halldórsdóttir AM; Hrafnkelsson B; Einarsdóttir K; Kristinsson KG
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1689-1697. PubMed ID: 38935227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
    Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
    Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?
    Ahn ST; Kim SW; Kim JW; Park HS; Moon DG; Oh MM
    J Infect Chemother; 2019 Jul; 25(7):498-502. PubMed ID: 30852104
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
    Celik AD; Yulugkural Z; Kuloglu F; Eroglu C; Torol S; Vahaboğlu H; Akata F
    J Microbiol Immunol Infect; 2010 Apr; 43(2):163-7. PubMed ID: 20457435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevalence and types of extended-spectrum beta-lactamases among urinary Escherichia coli and Klebsiella spp. in New Zealand.
    Heffernan HM; Woodhouse RE; Pope CE; Blackmore TK
    Int J Antimicrob Agents; 2009 Dec; 34(6):544-9. PubMed ID: 19748232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.